RESEARCH USE ONLY · NOT FOR HUMAN CONSUMPTION
LOS ANGELES, CA · SAME-DAY DISPATCH
SCALEPEPTIDES Book a supply call
Answers

What does Mastercard BRAM mean for research peptide sellers?

PaymentsComplianceUpdated 2026-08-23
The short answer

BRAM is Mastercard’s Business Risk Assessment and Mitigation program. Its 2026 update addressed research peptides and unapproved pharmaceuticals directly, which removed the ambiguity acquirers had been operating inside.

The practical effect is that banks now either underwrite the category knowingly and strictly, or leave it. There is much less middle ground than there was two years ago.

The program acts on banks, not merchants

This is the part merchants consistently misunderstand. BRAM assesses the acquiring bank for merchants in its portfolio that breach network standards. The consequence lands on the bank, which passes it down.

That is why processor behaviour in a category can change overnight with no notice to you. Nothing about your business changed. Your acquirer’s own exposure did.

What the update changed in practice

What actually triggers an assessment

Three of those four are entirely within a merchant’s control, which is the useful takeaway. The category is harder than it was; the individual merchant’s conduct is still the variable that decides most outcomes.

What this means for choosing a partner Ask any payments vendor how many acquiring relationships they hold and whether any currently underwrite your exact category. A vendor with one relationship and a confident manner is a single point of failure. A vendor promising approval does not understand who makes the decision.

References

  1. Mastercard BRAM violations and card brand disputes, TFM Law
  2. Mastercard Business Risk Assessment and Mitigation overview

Related

Supply call

Bring your hardest question.

Ari runs supply intake. Thirty minutes on your catalog, your labeling, your fulfillment and your payments position — including when the answer is that we are the wrong supplier for you.

Ari
Supply & partnerships · Scale Peptides